Australia markets close in 58 minutes
  • ALL ORDS

    6,759.40
    -57.40 (-0.84%)
     
  • ASX 200

    6,535.90
    -65.20 (-0.99%)
     
  • AUD/USD

    0.7390
    +0.0001 (+0.01%)
     
  • OIL

    45.04
    -0.49 (-1.08%)
     
  • GOLD

    1,773.10
    -15.00 (-0.84%)
     
  • BTC-AUD

    25,079.00
    +280.69 (+1.13%)
     
  • CMC Crypto 200

    365.53
    +28.03 (+8.31%)
     
  • AUD/EUR

    0.6172
    -0.0001 (-0.02%)
     
  • AUD/NZD

    1.0511
    +0.0000 (+0.00%)
     
  • NZX 50

    12,670.74
    +30.91 (+0.24%)
     
  • NASDAQ

    12,258.21
    +351.81 (+2.95%)
     
  • FTSE

    6,367.58
    +4.65 (+0.07%)
     
  • Dow Jones

    29,910.37
    +37.87 (+0.13%)
     
  • DAX

    13,335.68
    +208.68 (+1.59%)
     
  • Hang Seng

    26,771.65
    -123.03 (-0.46%)
     
  • NIKKEI 225

    26,626.87
    -17.84 (-0.07%)
     

Geron to Announce Third Quarter Financial Results on November 5, 2020

·1-min read

Geron Corporation (Nasdaq: GERN) today announced that it will release its third quarter 2020 financial results after the market closes on Thursday, November 5, 2020 via press release, which will be available on the Company’s website at www.geron.com/investors. Geron will host a conference call to discuss the financial results as well as recent events at 4:30 p.m. ET the same day.

A live, listen-only webcast will be available on the Company’s website at www.geron.com/investors/events. If you are unable to listen to the live call, an archived webcast will be available on the Company’s website for 30 days.

Participants may access the conference call live via telephone by pre-registering online using the following link, http://www.directeventreg.com/registration/event/7879966. Upon registration, a phone number, Direct Event Passcode and unique Registrant ID will be sent via email. This information will be needed in order to enter the conference call. Participants are advised to pre-register at least 10 minutes prior to joining the call.

About Geron

Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. For more information about Geron, visit www.geron.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201029006250/en/

Contacts

Suzanne Messere
Investor and Media Relations
investor@geron.com
media@geron.com